Allergan recalls Taytulla contraceptive pills over packaging error

Allergan is recalling birth control pills that may be out of order in their packages. This package of Allergan Taytulla contraceptive capsules is correctly packaged with the four nonhormone tablets at the end. (Allergan)

Some U.S. women given a sample package of an Allergan birth control drug got more than they bargained for: the risk of an unwanted pregnancy.

The Dublin-based drugmaker, which has found itself in this kind of situation before, on Tuesday said it had issued a voluntary nationwide recall of 168,768 physician sample packs of Taytulla capsules. The action came after a physician discovered a package in which the first four days of therapy had four nonhormonal placebo capsules instead of active capsules.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Actavis yanks more than half a million boxes of birth control pills for packaging faux pas

The recall notice said that a Taytulla pill pack is a 28-count blister card with 24 "active" pink softgel capsules, the ones with the hormones, which are followed by 4 maroon softgel capsules that don’t have hormones. The packages are from lot #5620706, with an expiration date of May 2019.

Taking the capsules out of sequence because of the packaging error “may place the user at risk for contraceptive failure and unintended pregnancy,” Allergan said, adding the reversed of order may not be apparent to new users, or even previous users, of the product.

RELATED: Endo's Par recalls more than 1.3 million birth control pills made by Patheon

This kind of packaging error is not unheard of. In 2015, shortly after Allergan and Actavis completed a merger, Actavis recalled 26 lots, amounting to 511,283 boxes, of Lutera birth control pills after discovering that package inserts were missing. The pills were manufactured for Actavis by Patheon, the report indicates. Teva now owns most of the Actavis portfolio.

Last year, Endo’s Par recalled 162 lots, comprising 1,365,559 tablets, of its Gildess contraceptive in different dose sizes. The tablets were manufactured for Endo’s Qualitest Pharmaceuticals unit by Patheon at a plant in Ontario, Canada. In that case, the pills, a combination of norethindrone acetate and ethinyl estradiol, were recalled for being subpotent for ethinyl estradiol.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.